Publications by authors named "H Skouri"
Am J Cardiol
October 2024
Article Synopsis
- Cardiac amyloidosis (CA) is an often overlooked cause of heart failure (HF), highlighting the importance of early detection and timely therapy for better patient outcomes.
- A global survey with 1,460 physicians revealed that while many have experience diagnosing CA in patients with preserved ejection fraction (HFpEF), systematic screening is not widely practiced, with only 10% conducting routine checks.
- There is significant variability in screening and management strategies for CA, indicating a need for better education and access to disease-modifying therapies within the HF community.
Article Synopsis
- Left ventricular assist devices (LVADs) are commonly used to treat advanced heart failure, improving survival but leading to high rates of arrhythmias (20-50%) within a year after implantation.
- Arrhythmias in these patients increase the risk of complications, such as additional shocks from implantable defibrillators and potential worsening of right ventricular failure, highlighting the need for tailored management strategies.
- Effective treatment for these arrhythmias may involve specialized approaches like catheter ablation, though unique challenges exist in accessing arrhythmogenic areas after LVAD surgery, making pre-implantation procedures potentially beneficial.
Eur J Heart Fail
October 2024
Article Synopsis
- Immunological therapies, including immune checkpoint inhibitors (ICIs) and cell-based therapies like CAR-T, have transformed cancer treatment by enabling the immune system to target cancer cells.
- While these therapies are generally effective, they can cause immune-related adverse events (irAEs) that vary in severity and timing, from mild skin rashes to serious complications such as myocarditis or cytokine release syndrome.
- The statement discusses the growing understanding of cardiovascular toxicities associated with these therapies, outlines their diagnosis and management, and identifies gaps in current research that need further exploration.
Int J Cardiol
October 2024
Article Synopsis
- - The prevalence of heart failure with preserved ejection fraction (HFpEF) is rising, leading to significant hospitalization (up to 80%) and mortality rates (50%) within five years, largely due to systemic inflammation and related cardiac dysfunction.
- - Diagnosing HFpEF is complex and relies on clinical assessments, imaging, biomarkers, and excluding other cardiac conditions that could mimic or contribute to HFpEF.
- - Treatments like sodium-glucose cotransporter 2 inhibitors, tailored therapies, exercise recommendations, and novel inflammation-targeting approaches show promise, especially for obese HFpEF patients who may benefit from glucagon-like peptide-1 agonists.
